Earlier this year, the "Cao Cao Chauffeured Car Services" was invested by a number of domestic and overseas institutions and successfully completed A-round financing of 1 billion yuan, with a valuation of more than 10 billion yuan. The equity was completed in the near future. The financial advisor of the "Cao Cao Chauffeured Car Services" Series A financing was held by the Zhejiang Branch of China Construction Bank. The project's achievements have received great attention from the investment market. “Cao Cao Chauffeured Car Services” is a strategic service platform for...
Release time:
2018
-
06
-
11
浏览次数：20
On June 6, 2018, Hong Kong – China Ebgreentech Co., Ltd. (“Ebgreentech” or “Company”) (Hong Kong stock code: 1257) is pleased to announce that the company has recently acquired the Gansu Linyi Biomass and Waste Power Integration Project ( Waste-to-energy (“Linfen Project”) and Jiangsu Coastal Hazardous Waste Incineration Project (“Binhai Project”) involve a total investment of approximately RMB 616 million.The Linyi project involves an investment of approximately RMB 287 million, a design scale of daily processing of 500 tons of domestic waste, construction of a BOT (build-operate-transfer) mo...
Release time:
2018
-
06
-
11
浏览次数：23
On the morning of June 6, the leaders of the Hubei Provincial Joint Development Investment Group (hereinafter referred to as “Liantou Group”) and Donghu High-tech leaders visited our company to conduct in-depth exchanges and discussions on promoting cooperation between the two sides. Deputy General Manager Ding Zhenguo of Lianyuan Group, Huang Min, Director of the Human Resources Department, and Yang Tao, Chairman of Wuhan Donghu High-tech Group attended the symposium. He Xiangdong, CEO of our company, Wang Hongbin, Managing Partner, and She Zhihong, Vice President of Silicon Paradise Wuhan Br...
Release time:
2018
-
06
-
11
浏览次数：74
In recent years, with the continuous improvement of the economic level, the general public has increasingly attached importance to medical and health care, and China’s medical and health industry has entered a period of rapid development. In the “Thirteenth Five-Year Plan”, healthy China has been upgraded to a “national strategy” and is expected to become an important source of new economic growth. The country’s medical consumption needs will further expand, and the health industry’s consumer market will show a huge amount. Potential and development vitality. This has also attracted a lar...
Release time:
2018
-
06
-
11
浏览次数：21
Note: Starry is a company invested by TTGGZhejiang Starry Pharmaceutical Co., Ltd. (603520) disclosed the revised draft of the reorganization draft on the evening of June 4. The company plans to issue 27.8293 million shares at 26.95 yuan/share, and to pay 100 million yuan in cash for a total purchase price of 850 million yuan to acquire 100% equity of Hisyn Pharmaceuticals. Supporting fund-raising does not exceed 150 million yuan. Haishen Pharmaceutical Co., Ltd. is mainly engaged in iodine contrast agent APIs. The net profit promised from 2018 to 2020 is not less than RMB 43.7461 million, RMB...
Release time:
2018
-
06
-
06
浏览次数：39